Kidney Fibrosis - Pipeline Review, H1 2020

April 2020 | 174 pages | ID: K9F1CAC6BE9EN
Global Markets Direct

Abstracts

Kidney Fibrosis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2020, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 34 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Kidney Fibrosis - Overview
Kidney Fibrosis - Therapeutics Development
Kidney Fibrosis - Therapeutics Assessment
Kidney Fibrosis - Companies Involved in Therapeutics Development
Kidney Fibrosis - Drug Profiles
Kidney Fibrosis - Dormant Projects
Kidney Fibrosis - Discontinued Products
Kidney Fibrosis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Kidney Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Kidney Fibrosis - Pipeline by AdAlta Ltd, H1 2020
Kidney Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H1 2020
Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H1 2020
Kidney Fibrosis - Pipeline by Blade Therapeutics Inc, H1 2020
Kidney Fibrosis - Pipeline by Cellmid Ltd, H1 2020
Kidney Fibrosis - Pipeline by Curacle Co Ltd, H1 2020
Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H1 2020
Kidney Fibrosis - Pipeline by Evotec SE, H1 2020
Kidney Fibrosis - Pipeline by Future Medicine Co Ltd, H1 2020
Kidney Fibrosis - Pipeline by Galapagos NV, H1 2020
Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2020
Kidney Fibrosis - Pipeline by GenKyoTex SA, H1 2020
Kidney Fibrosis - Pipeline by iBio Inc, H1 2020
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2020
Kidney Fibrosis - Pipeline by Kadmon Corp LLC, H1 2020
Kidney Fibrosis - Pipeline by Liminal BioSciences Inc, H1 2020
Kidney Fibrosis - Pipeline by Max Biopharma Inc, H1 2020
Kidney Fibrosis - Pipeline by MedPacto Inc, H1 2020
Kidney Fibrosis - Pipeline by Mission Therapeutics Ltd, H1 2020
Kidney Fibrosis - Pipeline by NB Health Laboratory Co Ltd, H1 2020
Kidney Fibrosis - Pipeline by Novo Nordisk AS, H1 2020
Kidney Fibrosis - Pipeline by Oasis Pharmaceuticals LLC, H1 2020
Kidney Fibrosis - Pipeline by Osteoneurogen Inc, H1 2020
Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H1 2020
Kidney Fibrosis - Pipeline by Redx Pharma Plc, H1 2020
Kidney Fibrosis - Pipeline by Sanofi, H1 2020
Kidney Fibrosis - Pipeline by Scholar Rock Inc, H1 2020
Kidney Fibrosis - Pipeline by Senolytic Therapeutics Inc, H1 2020
Kidney Fibrosis - Pipeline by TiumBio Co Ltd, H1 2020
Kidney Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H1 2020
Kidney Fibrosis - Pipeline by Transcenta Holding Ltd, H1 2020
Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2020
Kidney Fibrosis - Pipeline by Vectus Biosystems Ltd, H1 2020
Kidney Fibrosis - Dormant Projects, H1 2020
Kidney Fibrosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Kidney Fibrosis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Kidney Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AdAlta Ltd
Algernon Pharmaceuticals Inc
Angion Biomedica Corp
BiOrion Technologies BV
Blade Therapeutics Inc
Cellmid Ltd
Curacle Co Ltd
Epigen Biosciences Inc
Evotec SE
Future Medicine Co Ltd
Galapagos NV
Galectin Therapeutics Inc
GenKyoTex SA
iBio Inc
Isarna Therapeutics GmbH
Kadmon Corp LLC
Liminal BioSciences Inc
Max Biopharma Inc
MedPacto Inc
Mission Therapeutics Ltd
NB Health Laboratory Co Ltd
Novo Nordisk AS
Oasis Pharmaceuticals LLC
Osteoneurogen Inc
Pharmaxis Ltd
Redx Pharma Plc
Sanofi
Scholar Rock Inc
Senolytic Therapeutics Inc
TiumBio Co Ltd
TRACON Pharmaceuticals Inc
Transcenta Holding Ltd
Vascular Biogenics Ltd
Vectus Biosystems Ltd